CRSP:NSD-CRISPR Therapeutics AG (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 59.6

Change

-0.97 (-1.60)%

Market Cap

USD 0.79B

Volume

1.26M

Analyst Target

USD 95.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CRISPR Therapeutics AG is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.13 (-0.24%)

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

+7.30 (+0.69%)

USD 115.08B
MRNA Moderna Inc

+0.60 (+0.44%)

USD 51.07B
ALNY Alnylam Pharmaceuticals Inc

+17.25 (+7.74%)

USD 28.20B
ARGX argenx NV ADR

+10.96 (+2.49%)

USD 26.78B
BNTX BioNTech SE

-2.23 (-2.57%)

USD 20.40B
BGNE BeiGene Ltd

-8.16 (-5.13%)

USD 17.50B
GMAB Genmab AS

-0.04 (-0.15%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.17 (-0.20%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.21 (-0.77%)

USD 15.90B

ETFs Containing CRSP

XDNA 15.28 % 0.00 %

N/A

N/A
ARKG 8.19 % 0.75 %

N/A

N/A
ARCG:LSE ARK Genomic Revolution UC.. 7.47 % 0.00 %

-5.10 (-0.36%)

USD 2.44M
ARKK ARK Innovation ETF 5.72 % 0.75 %

+0.09 (+-0.36%)

USD 6.24B
ARCK:LSE ARK Innovation UCITS ETF .. 5.04 % 0.00 %

-1.30 (-0.36%)

USD 5.48M
GNOM Global X Genomics & Biote.. 4.28 % 0.00 %

-0.11 (-0.36%)

USD 0.09B
GNOG:LSE Global X Genomics & Biote.. 4.21 % 0.00 %

-0.03 (-0.36%)

USD 6.81M
NXTE Investment Managers Serie.. 3.86 % 0.00 %

-0.06 (-0.36%)

USD 0.06B
LS:CA Middlefield Healthcare & .. 3.11 % 2.21 %

N/A

CAD 0.16B
CBLS Listed Funds Trust - Chan.. 2.50 % 0.00 %

+0.25 (+-0.36%)

USD 0.03B
AIIQ 0.00 % 0.79 %

N/A

N/A
ERSX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.79% 60% D- 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.79% 60% D- 46% F
Trailing 12 Months  
Capital Gain 4.67% 72% C 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.67% 72% C 56% F
Trailing 5 Years  
Capital Gain 31.25% 78% C+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.25% 78% C+ 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 22.40% 76% C+ 80% B-
Dividend Return 22.40% 76% C+ 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.75% 39% F 22% F
Risk Adjusted Return 30.37% 84% B 65% D
Market Capitalization 0.79B 95% A 89% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.53 36% 59%
Price/Book Ratio 2.74 49% 37%
Price / Cash Flow Ratio -19.94 92% 88%
Price/Free Cash Flow Ratio -18.23 94% 89%
Management Effectiveness  
Return on Equity -11.02% 93% 49%
Return on Invested Capital -12.00% 82% 38%
Return on Assets -7.97% 91% 37%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.